Under construction – not a live service
Sign in
Taking people in GermanyPhase 1

Etentamig or ABBV-519 for lupus, rheumatoid arthritis and Sjögren's disease

Tests etentamig or ABBV-519 in adults with lupus, rheumatoid arthritis or Sjögren's disease.

Key facts

Who runs it
AbbVie Deutschland GmbH & Co. KG
Where
Berlin, GermanySee the site
Registry title
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
Status
Recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
17 Sept 2026
Expected to end
31 Mar 2029
Type of study
Interventional
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or Sjögren's disease (SjD). It tests etentamig or ABBV-519 for B cell depletion.

Age
18 years or older
Sex
All sexes can join
Disease stage
Moderate to severe systemic lupus erythematosus, rheumatoid arthritis or Sjögren's disease

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in Germany

  • Charite Research Organisation GmbHBerlin, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Etentamig or ABBV-519 for lupus, rheumatoid arthritis and Sjögren's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
10 September 2026